Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14376028 | 0.83 | ALDH1A1 (0.45) | ALDH1A1OPRK1HPGDKHKLRRK2 | |
| SCHEMBL2366907 | 0.81 | HRH4 (0.48) | TSHRCYP1A2MEN1KMT2A | |
| SCHEMBL30593370 | 0.81 | HRH4 (0.48) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL2710577 | 0.80 | KDM4E (0.46) | ALDH1A1MAPK1OPRK1HPGDTSHR | |
| SCHEMBL1707909 | 0.80 | KDM4E (0.51) | ALDH1A1MAPK1OPRK1HPGDTSHR | |
| SCHEMBL2144542 | 0.80 | KDM4E (0.46) | ALDH1A1HPGDTSHRKHKLRRK2 | |
| SCHEMBL31195824 | 0.80 | KDM4E (0.51) | ALDH1A1MAPK1OPRK1HPGDTSHR | |
| SCHEMBL18307138 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPK1HPGDTSHRKHK | |
| SCHEMBL21262656 | 0.80 | KDM4E (0.47) | ALDH1A1MAPK1HPGDTSHRKHK | |
| SCHEMBL28663339 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPK1HPGDTSHRKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2023-09-28 | — | — | US | disclosed |
| WO-2023131271-A1 | PYRROLE FUSED-RING PYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| EP-3722284-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2020-10-14 | — | — | EP | disclosed |
| US-9580437-B2 | Triazolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2017-02-28 | — | — | US | disclosed |
| WO-2016103155-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2016-06-23 | — | — | US | disclosed |
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931363-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | ALDH1A1 529/4885MAPK1 690/4885OPRK1 4678/4885 |
| US-11207325-B2 | Triazolopyrimidine compounds and uses thereof | EZH2, DOT1L, EED | ALDH1A1 529/4885MAPK1 690/4885OPRK1 4678/4885 |
| US-20200323859-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | ALDH1A1 529/4885MAPK1 690/4885OPRK1 4678/4885 |
| US-20230303573-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | ALDH1A1 337/4885MAPK1 2996/4885OPRK1 1/4885 |
| US-20240216378-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | ALDH1A1 529/4885MAPK1 690/4885OPRK1 4678/4885 |
| US-20160176882-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | ALDH1A1 529/4885MAPK1 690/4885OPRK1 4678/4885 |
| US-20230033320-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | ALDH1A1 529/4885MAPK1 690/4885OPRK1 4678/4885 |
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | ALDH1A1 3930/4885MAPK1 326/4885OPRK1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.